Rank Product Manufacturer Primary indication(s) 2016 US sales $ (millions) 2015 US sales $ (millions) % change
1 Prolia Amgen osteoporosis $1,049.0 $837.0 25%
2 Premarin Pfizer atrophic vaginitis; osteoporosis $956.0 $951.0 1%
3 Mirena Bayer female contraception $776.0 $709.0 9%
4 Forteo Eli Lilly osteoporosis $771.0 $612.0 26%
5 NuvaRing Merck & Co female contraception $576.0 $515.0 12%
6 Nexplanon Merck & Co female contraception $420.0 $367.0 14%
7 Lo Loestrin FE Allergan female contraception $404.0 $347.0 16%
8 Estrace Cream Allergan atrophic urethritis $379.0 $326.0 16%
9 Makena AMAG Pharmaceuticals premature delivery $334.0 $252.0 33%
10 Minastrin 24 FE Allergan female contraception $326.0 $272.0 20%
11 Vagifem Novo Nordisk atrophic vaginitis $302.0 $332.0 -9%
12 Lupron AbbVie uterine fibroids; endometriosis $285.0 $280.0 2%
13 Gonal-F Merck KGaA female infertility $221.0 $193.0 15%
14 Follistim Merck & Co female infertility $157.0 $160.0 -2%
15 Yasmin Bayer female contraception $142.0 $149.0 -5%
16 Oral Contraceptive Franchise Johnson & Johnson/Pfizer * female contraception $129.0 $267.0 -52%
17 Natazia Bayer female contraception $104.0 $95.0 10%
18 Minivelle Hisamitsu Pharmaceutical menopause $88.0 $92.0 -4%
19 Caltrate Pfizer osteoporosis $87.0 $85.0 2%
20 Junel/Loestrin Teva Pharmaceutical Industries female contraception $79.0 $74.0 7%
21 Cervidil Allergan cervical ripening $58.0 $58.0 0%
22 Evista Eli Lilly osteoporosis $50.0 $62.0 -18%
23 Apri Teva Pharmaceutical Industries female contraception $45.0 $45.0 0%
24 Crinone Allergan female infertility $40.0 $40.0 0%
25 Lidocaine HCl Jelly Amphastar Pharmaceuticals amenorrhoea $37.0 $30.0 23%

* indicates sales figures for this product represent franchise-level sales that have been assigned by Evaluate to the lead product in the Franchise

Source: EvaluatePharma, August 2017, Evaluate, www.evaluate.com

From the October 01, 2017 Issue of MM+M - Medical Marketing and Media